publication date: Aug. 3, 2018
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
Project GENIE, already the largest publicly available genomic data repository in the U.S., is on track to publish information on 60,000 sequenced tumors—derived from an international network largely comprised of academic cancer centers—by January 2019.
Researchers at Project GENIE, the largest publicly available genomic database in the U.S., understand what it takes to convert sequencing data into real-world evidence: a lot of money, manpower, and data harmonization, said Shawn Sweeney, director of the American Association for Cancer Research Project GENIE Coordinating Center.
The House Committee on Appropriations has withheld funding for the WHO International Agency for Research on Cancer—which receives about $2 million from the United States per year—because of controversy over the agency’s label for glyphosate, a chemical commonly used in weedkillers.
- University of Minnesota Masonic Cancer Center receives “outstanding” rating
- Dominic Seraphin named VP of Strategic Alliances & Network at Moffitt
- Constanza Martinez Piñanez joins Miami Cancer Institute
- Study identifies genes associated with risk for triple negative breast cancer
- Lung cancer mortality rates in women to increase worldwide by over 40 percent by 2030
- Tumor Treating Fields + paclitaxel may improve survival in ovarian cancer
- FDA approves first treatment for rare adrenal tumors
- TheraBionic P1 device receives European regulatory approval
- Keytruda + pemetrexed and platinum gets EMA’s positive opinion for first-line NSCLC
- Tafinlar + Mekinist gets positive CHMP opinion for adjuvant BRAF V600 mutation-positive melanoma
- Lenvima + Keytruda get Breakthrough designation for endometrial carcinoma
- Pfizer receives European approval for biosimilar trastuzumab
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.